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DEAR EDITOR, Priority setting partnerships give patients and
heathcare professionals an equal voice in driving priorities for
future research. This ensures that research answers the most
important questions needed to inform clinical practice.1
Cellulitis (also known as erysipelas) is an acute, often recur-
rent, infection of the skin and underlying tissue. It is painful,
and repeated episodes lead to progressive damage to the
lymph system and skin integrity, leading to lymphoedema and
ulceration.2 The condition has received relatively little research
attention to date, and systematic reviews have identified
important evidence gaps.3,4
This letter describes the results of a recent Cellulitis Priority
Setting Partnership, which has identified the top 10 most
important questions for future research. Three of the priori-
tized questions address issues around diagnosis of cellulitis,
four about treatment and three about prevention of repeat
episodes.
The Cellulitis Priority Setting Partnership took place from
January 2016 to April 2017 following a standard methodology
as outlined in the James Lind Alliance guidebook (www.jla.nih
r.ac.uk/jla-guidebook). Full details of the protocol are avail-
able (www.nottingham.ac.uk/dermatology). In brief, we
conducted an online survey using SurveyMonkey software,
from April to June 2016, to gather the views of patients and
healthcare professionals (Table 1). This survey was supple-
mented by evidence gaps identified from systematic reviews
and guidelines published in the last 3 years (www.nottingha
m.ac.uk/research/groups/cebd/resources/maps-of-systematic-
reviews.aspx).
Overall, 846 uncertainties were submitted, of which 639
contained a specific question about the diagnosis or manage-
ment of cellulitis. Submitted uncertainties were combined and
refined, to produce a list of 40 ‘unique uncertainties’ that
reflected the broad themes of the individual submissions. Dur-
ing this collation and rewording stage, input from the lay
members of the steering group ensured that all questions were
worded clearly in language understood by the general public.
We avoided value-laden statements such as ‘What is the role
of . . . ?’, which could imply that the treatment is beneficial.
Instead a more neutral form of wording was used, such as ‘Is
there a role for . . .’ or ‘Could xxxx help to . . . ?’.
A second online survey took place between December 2016
and February 2017. This interim prioritization survey was
completed by 352 participants (Table 1), who were asked to
vote for their top 10 priority questions from the 40
Table 1 Characteristics of participants
First survey Second survey Final workshop
Patient with single episode of cellulitis 33 (823)a 38 (1076)b 1c
Patient with multiple episodes of cellulitis 111 (2768)a 125 (3541)b 10c
Both patient and healthcare professional 1 (025)a 8 (227)b Information
not collected
Carer of patient with cellulitis 7 (175) 16 (453) –
Patient (other) 19 (474) 3 (085) 1c
Dermatology doctor 66 (1646) 38 (1076) 3
General practitioner/family doctor 87 (2170) 54 (1530) 5
Emergency doctor 3 (075) 8 (227)
Nurse 19 (474) 20 (567) 6
Lymphoedema or infection doctor 30 (748) 28 (793) 2
Healthcare professional (other) 12 (299) 7 (198) –
Other 13 (324) 8 (227) –
Total 401 353 28
All data are presented as n (%) unless otherwise stated. aOf the 152 patient respondents, 92 (605%) had lymphoedema, five (33%) had
diabetes, six (39%) had both conditions and 49 (322%) participants did not provide this information. bOf the 187 patient respondents,
107 (572%) had lymphoedema, six (32%) had diabetes, 15 (80%) had both, 57 (305%) had neither condition, and two participants
(107%) did not provide this information. cOf the 12 patient participants, eight (67%) had lymphoedema and one (8%) had diabetes.
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uncertainties identified during the previous stage. Uncertain-
ties were presented to individuals in a random order to mini-
mize selection bias. Participants were first asked to select all
uncertainties they felt were important. These selections were
then re-presented to the participants and they were asked to
choose their top 10 questions from the resulting list. Partici-
pants were then asked to choose just three of their 10 that
they felt were ‘most important’ to them.
Once all responses had been submitted, the steering group
agreed on additional merging/rewording of 11 uncertainties
to ensure that all topics in the priority list were broadly com-
parable in terms of breadth (e.g. specific questions about how
best to prevent cellulitis were combined into a single uncer-
tainty on the best way to prevent cellulitis that did not involve
use of antibiotics). This resulted in a revised list of 29 uncer-
tainties from the interim prioritization stage.
Table 2 Results of Cellulitis Priority Setting Partnership: top 20 uncertainties
Final rank order
following workshop Questions discussed at workshop
Rank order from survey
(prior to workshop)
1 aHow can healthcare professionals be best supported to accurately diagnose and manage
cellulitis and to advise their patients in how to prevent relapses?
6
2 What are the best diagnostic criteria for cellulitis, and are they different for different patient
groups (e.g. people with lymphoedema)?
3
3 When treating cellulitis, could a higher initial dose and/or longer course of antibiotics result
in a faster recovery and/or fewer relapses?
2
4 bWhat is the best nonantibiotic intervention for the prevention of cellulitis (e.g. skin care;
foot care; moisturisers; antiseptics; lifestyle changes such as weight loss and exercise;
compression garments/bandages; treating athlete’s foot; complementary and alternative
therapy)?
1
5 Does rest/elevation during an episode of cellulitis help to speed up recovery and improve
symptoms, compared with exercise/movement of the affected limb?
8
6 Is the duration, dose and method of administration of antibiotics needed to treat cellulitis
related to patient characteristics (e.g. patients with diabetes who are overweight or have
swelling of the limb may require a higher dose/duration)?
19
7 What are the early signs and symptoms of cellulitis that can help to ensure speedy
treatment?
7
8 What type of patients are most likely to benefit from low-dose antibiotics to prevent
repeated episodes of cellulitis?
15
9 cIs there a role for the use of compression garments/bandages on the affected limb during
an episode (when tolerable), or immediately following an episode of cellulitis, to speed recovery and reduce
complications and recurrence?
20
10 How safe are long-term antibiotics for the prevention of recurrent cellulitis? 10
11 What is the best and safest antibiotic, or combination of antibiotics, to treat cellulitis? 4
12 When treating an episode of cellulitis, what features should prompt a change in antibiotic
treatment and after what duration?
13
13 Which patients are most likely to benefit from intravenous antibiotics (as inpatient or
outpatient) for the treatment of cellulitis?
17
14 Can testing (e.g. blood tests or scans) help to give a faster or more accurate diagnosis of
cellulitis?
5
15 What is the best way to ensure speedy treatment of recurrent cellulitis (e.g. keeping
antibiotics at home)?
16
16 What are the most appropriate antibiotics for the prevention of cellulitis (including those for
patients allergic to penicillin)?
18
17 What is the best treatment to use first when treating cellulitis? 11
18 For how long should low-dose antibiotics be taken to prevent repeat episodes of cellulitis? 14
19 dIs there a role for testing to check that the infection has completely cleared before stopping
treatment for cellulitis?
12
20 dIs there a role for tests to identify the type of bacteria causing the cellulitis in deciding the
best treatment option?
9
aThis uncertainty includes the development of tests or tools to assist with the diagnosis and management of cellulitis. bUncertainty combined
and reworded by the steering group following the interim priority setting survey. Number of votes for each in the interim survey: moisturis-
ers (58 votes); compression garments/bandages (50 votes); lifestyle changes, e.g. diet, weight loss, exercise (52 votes); complementary and
alternative therapy (46 votes); treatment of fungal foot disease (44 votes); antiseptics following injury (36 votes); improved foot care (30
votes); and regular washing (19 votes). cCompression considered to be too painful during the initial acute episode. As a result, minor modi-
fication of the wording was agreed by the steering group after the workshop (italicized words added). dConsidered important areas to watch
for future developments.
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In order to select a shortlist of approximately 20 uncertain-
ties for discussion at the final prioritization workshop, the
steering group reviewed the results of the interim prioritiza-
tion survey (based on individuals’ top 10 selections), pre-
sented in rank order for all responders combined, and then
separately for patients and healthcare professionals. Uncertain-
ties were selected for consideration at the final workshop if
they were ranked in the top 20 for patients or healthcare pro-
fessionals and were in the top 20 for all responders on the
basis of rank order of choices when selecting their top three
uncertainties.
Twenty uncertainties were agreed for discussion at the final
workshop, which took place in London on 21 April 2017.
This whole-day, face-to-face consensus meeting involved 12
patients, 16 healthcare professionals and two observers
(Table 1). Nominal group techniques were employed to
achieve consensus on the top 10 research priorities, using a
combination of whole-group and small-group discussions.
Details of the 20 uncertainties that were discussed at the face-
to-face meeting, along with their finalized ranking, are sum-
marized in Table 2.
Results of this priority setting partnership will now be pub-
licized through academic journals, professional networks and
social media channels. Uncertainties will be worked up into
detailed research questions and submitted to relevant funding
bodies. This work has identified a community of patients and
healthcare professionals who are interested in conducting and
contributing to cellulitis research. We hope that this priority
setting partnership will encourage this community to work
together to address these important research gaps.
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